Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced that its representatives will participate in the IPAC-RS 2026 Nasal Innovation Forum, scheduled for September 16-17, 2026, in Jersey City, New Jersey. The forum provides a platform for industry experts to discuss advancements in nasal drug development, an area of strategic importance for Silo as it advances its lead candidate, SPC-15, designed for the treatment of post-traumatic stress disorder (PTSD) through a novel nose-to-brain delivery approach.
SPC-15 leverages intranasal administration to target the central nervous system directly, potentially offering faster onset and improved efficacy compared to traditional systemic delivery methods. Recent preclinical data demonstrated that the SPC-15 formulation and device met predefined specifications for assay, impurities, pH, and microbiological quality over a nine-month period. Additionally, six-month accelerated stability data were consistent and aligned with long-term stability trends, indicating the formulation's robustness and commercial viability.
CEO Eric Weisblum emphasized the importance of the forum in fostering collaboration and knowledge exchange with peers in nasal drug development. "We look forward to engaging with experts at the IPAC-RS Nasal Innovation Forum as we continue to advance SPC-15's innovative approach to targeted drug delivery," said Weisblum. "The stability data we have generated reinforce our confidence in the program's potential to address the significant unmet need in PTSD treatment."
The company's participation highlights its commitment to developing differentiated therapies for underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Beyond SPC-15, Silo's pipeline includes SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer's disease and multiple sclerosis. These programs are developed in collaboration with leading universities and research institutions, leveraging cutting-edge science to bring novel treatments to patients.
Silo Pharma's involvement in the IPAC-RS forum is a strategic move to network with key opinion leaders and potential partners, potentially accelerating the path to clinical development. The positive stability data announced earlier this year mark a critical milestone for SPC-15, reducing formulation risks and positioning the program for future investigational new drug (IND) filing and clinical trials. This progress is significant given the high prevalence of PTSD and the limitations of current therapies, which often have delayed onset of action or significant side effects.
The company's innovative approach extends beyond its therapeutic pipeline. Silo Pharma also operates a wholly owned managed AI agent platform, reflecting its forward-thinking strategy to integrate technology into drug development and delivery. This dual focus on biotechnology and artificial intelligence positions the company uniquely in the biopharmaceutical landscape.
Investors and industry observers will be watching Silo Pharma's progress closely as it continues to advance its pipeline and present at key industry conferences. The IPAC-RS 2026 Nasal Innovation Forum offers an ideal venue for Silo to showcase its nasal drug delivery expertise and forge collaborations that could enhance its development capabilities. The company's participation underscores its dedication to addressing complex CNS disorders through innovative delivery mechanisms, potentially offering new hope for patients suffering from PTSD and other chronic conditions.
